TY - JOUR
T1 - Development and Validation of Test for “Leaky Gut” Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults
AU - Khoshbin, Katayoun
AU - Khanna, Lehar
AU - Maselli, Daniel
AU - Atieh, Jessica
AU - Breen-Lyles, Margaret
AU - Arndt, Kayla
AU - Rhoten, Deborah
AU - Dyer, Roy B.
AU - Singh, Ravinder J.
AU - Nayar, Sunita
AU - Bjerkness, Sandra
AU - Harmsen, William S.
AU - Busciglio, Irene
AU - Camilleri, Michael
N1 - Funding Information:
Funding This work was supported by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) (through an ILSI North America Carbohydrate Committee grant). IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. ILSI North America receives support primarily from its industry membership. ILSI North America had no role in the design, analysis, interpretation, or presentation of the data and results. Dr Camilleri receives funding for studies on intestinal permeability in irritable bowel syndrome (unrelated to current project) from the National Institutes of Health (R01 DK115950). The study was conducted in the Mayo Clinic Clinical Research Trials Unit, supported in part by nursing, dietetic, physiology, and immunochemistry laboratory components, which are supported by grant number UL1-TR002377 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Funding This work was supported by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) (through an ILSI North America Carbohydrate Committee grant). IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. ILSI North America receives support primarily from its industry membership. ILSI North America had no role in the design, analysis, interpretation, or presentation of the data and results. Dr Camilleri receives funding for studies on intestinal permeability in irritable bowel syndrome (unrelated to current project) from the National Institutes of Health (R01 DK115950). The study was conducted in the Mayo Clinic Clinical Research Trials Unit, supported in part by nursing, dietetic, physiology, and immunochemistry laboratory components, which are supported by grant number UL1-TR002377 from the National Center for Advancing Translational Sciences . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2021 The Authors
PY - 2021/8
Y1 - 2021/8
N2 - Background: Oral monosaccharides and disaccharides are used to measure in vivo human gut permeability through urinary excretion. Aims: The aims were as follows: (1) to obtain normative data on small intestinal and colonic permeability; (2) to assess variance on standard 16 g fiber diet performed twice; (3) to determine whether dietary fiber influences gut permeability measurements; and (4) to present pilot data using 2 selected probes in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: Sixty healthy female and male adults, age 18–70 years, participated in 3 randomized studies (2 studies on 16.25 g and 1 study on 32.5 g fiber) in otherwise standardized diets. At each test, the following sugars were ingested: 12C-mannitol, 13C-mannitol, rhamnose (monosaccharides), sucralose, and lactulose (disaccharides). Standardized meals were administered from 24 hours before and during 24 hours post-sugars with 3 urine collections: 0–2, 2–8, and 8–24 hours. Sugars were measured using high-performance liquid chromatography–tandem mass spectrometry. Eighteen patients with IBS-D underwent 24-hour excretion studies after oral 13C-mannitol and lactulose. Results: Baseline sugars (>3-fold above lower limits of quantitation) were identified in the 3 studies: 12C-mannitol in all participants; sucralose in 4–8, and rhamnose in 1–3. Median excretions/24 h (percentage of administered dose) for 13C-mannitol, rhamnose, lactulose, and sucralose were ∼30%, ∼15%, 0.32%, and 2.3%, respectively. 13C-mannitol and rhamnose reflected mainly small intestinal permeability. Intraindividual saccharide excretions were consistent, with minor differences with 16.25 g vs 32.5 g fiber diets. Median interindividual coefficient of variation was 76.5% (10–90 percentile: 34.6–111.0). There were no significant effects of sex, age, or body mass index on permeability measurements in health. 13C-mannitol measurements are feasible in IBS-D. Conclusions: Baseline 12C-mannitol excretion precludes its use; 13C-mannitol is the preferred probe for small intestinal permeability.
AB - Background: Oral monosaccharides and disaccharides are used to measure in vivo human gut permeability through urinary excretion. Aims: The aims were as follows: (1) to obtain normative data on small intestinal and colonic permeability; (2) to assess variance on standard 16 g fiber diet performed twice; (3) to determine whether dietary fiber influences gut permeability measurements; and (4) to present pilot data using 2 selected probes in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: Sixty healthy female and male adults, age 18–70 years, participated in 3 randomized studies (2 studies on 16.25 g and 1 study on 32.5 g fiber) in otherwise standardized diets. At each test, the following sugars were ingested: 12C-mannitol, 13C-mannitol, rhamnose (monosaccharides), sucralose, and lactulose (disaccharides). Standardized meals were administered from 24 hours before and during 24 hours post-sugars with 3 urine collections: 0–2, 2–8, and 8–24 hours. Sugars were measured using high-performance liquid chromatography–tandem mass spectrometry. Eighteen patients with IBS-D underwent 24-hour excretion studies after oral 13C-mannitol and lactulose. Results: Baseline sugars (>3-fold above lower limits of quantitation) were identified in the 3 studies: 12C-mannitol in all participants; sucralose in 4–8, and rhamnose in 1–3. Median excretions/24 h (percentage of administered dose) for 13C-mannitol, rhamnose, lactulose, and sucralose were ∼30%, ∼15%, 0.32%, and 2.3%, respectively. 13C-mannitol and rhamnose reflected mainly small intestinal permeability. Intraindividual saccharide excretions were consistent, with minor differences with 16.25 g vs 32.5 g fiber diets. Median interindividual coefficient of variation was 76.5% (10–90 percentile: 34.6–111.0). There were no significant effects of sex, age, or body mass index on permeability measurements in health. 13C-mannitol measurements are feasible in IBS-D. Conclusions: Baseline 12C-mannitol excretion precludes its use; 13C-mannitol is the preferred probe for small intestinal permeability.
KW - Barrier
KW - Lactulose
KW - Mannitol
KW - Sucralose
UR - http://www.scopus.com/inward/record.url?scp=85109077620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109077620&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.04.020
DO - 10.1053/j.gastro.2021.04.020
M3 - Article
C2 - 33865841
AN - SCOPUS:85109077620
SN - 0016-5085
VL - 161
SP - 463-475.e13
JO - Gastroenterology
JF - Gastroenterology
IS - 2
ER -